RxDoctor Payments Data

Killian Norton, PA

Physician Assistant · Fargo, NDNPI 1962057836

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $665 and has fallen 96.7% since, to $22 in 2025.

$1,155in general payments, 2019–2025

Across 67 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$208
  • Novo Nordisk$152
  • Mylan Specialty L.p.$98
  • Novartis$79
  • Johnson & Johnson$66
  • Merck$64
  • plus $487 from 14 others

What the payments were for

  • Food & beverage$1,155100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,155 in reported general payments places this provider in the 80th percentile of 355 physician assistant providers in North Dakota.

See all physician assistant providers in North Dakota

Medicare billing

Part B allowed, 2024
$3,867
Medicare patients
25
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$17,888
EliquisApixaban16$16,988
Gabapentin29$447
Rosuvastatin Calcium20$322
Levothyroxine Sodium31$311
Atorvastatin Calcium37$259
Losartan Potassium20$232
Tamsulosin Hcl11$229
Metoprolol Succinate12$191
Pantoprazole Sodium15$184
Oxycodone Hcl17$181
Amlodipine Besylate31$178
Simvastatin11$166
Metformin Hcl12$138
Tramadol Hcl19$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$152$17,88815 claims
PfizerEliquis$62$16,98816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 355 physician assistant providers in North Dakota.

Other physician assistant in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →